Ido Wolf

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter et al. · Clinical Cancer Research · 2014 · 662 citations

Medicine, Genetics, Oncology +17

Cyclophosphamide Triggers Follicle Activation and “Burnout”; AS101 Prevents Follicle Loss and Preserves Fertility

Lital Kalich‐Philosoph, Hadassa Roness, A. Carmely et al. · Science Translational Medicine · 2013 · 555 citations

Medicine, Cell Biology, Endocrinology +17

D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

Keren Merenbakh-Lamin, Noa Ben-Baruch, Adva Yeheskel et al. · Cancer Research · 2013 · 402 citations

Medicine, Endocrinology, Oncology +17

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

Harpreet Wasan, Navesh Sharma, Volker Heinemann et al. · The Lancet Oncology · 2017 · 398 citations · Full text

Medicine, Oncology, Radiation Oncology +17